KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBITDA Margin (2018 - 2025)

BioNTech SE's EBITDA Margin history spans 8 years, with the latest figure at 870.08% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 87009.0% to 870.08% in Q4 2025 year-over-year; TTM through Dec 2025 was 76.42%, a 7639.0% decrease, with the full-year FY2025 number at 48.95%, up 119095.0% from a year prior.
  • EBITDA Margin hit 870.08% in Q4 2025 for BioNTech SE, down from 3.09% in the prior quarter.
  • Over the last five years, EBITDA Margin for BNTX hit a ceiling of 307.74% in Q3 2024 and a floor of 5448.72% in Q2 2025.
  • Historically, EBITDA Margin has averaged 428.25% across 5 years, with a median of 43.41% in 2023.
  • Biggest five-year swings in EBITDA Margin: soared 29077bps in 2024 and later crashed -473745bps in 2025.
  • Tracing BNTX's EBITDA Margin over 5 years: stood at 84.95% in 2021, then fell by -9bps to 76.97% in 2022, then crashed by -54bps to 35.58% in 2023, then plummeted by -100bps to 0.0% in 2024, then plummeted by -19322219bps to 870.08% in 2025.
  • Business Quant data shows EBITDA Margin for BNTX at 870.08% in Q4 2025, 3.09% in Q3 2025, and 5448.72% in Q2 2025.